We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Iron Chelation Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00004982
First Posted: March 14, 2000
Last Update Posted: January 14, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
March 13, 2000
March 14, 2000
January 14, 2010
December 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004982 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Combination Iron Chelation Therapy
Not Provided
Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
  • Iron Overload
  • Thalassemia
Drug: Combination Iron Chelation Therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
November 2002
Not Provided

Inclusion Criteria:

  • Iron overload

Exclusion Criteria:

  • Overt cardiac disease
Sexes Eligible for Study: All
7 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00004982
CHELATION (completed)
1R01DK055463-01 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP